secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001213900-25-093930
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio submits Phase 2 MINDFuL manuscript; highlights subgroup benefit and no ARIA
--------------------------------------------------------------------------------

- Phase 2 MINDFuL trial of XPro1595 missed primary endpoint overall but showed positive trends in ADi subgroup with high inflammatory burden.
- No amyloid-related imaging abnormalities (ARIA) observed, even in high-risk patients (APOE4 carriers, anticoagulants, microbleeds).
- Manuscript submitted to npj Dementia (Nature Portfolio); preprint available on medRxiv.
- Expects FDA feedback for end-of-Phase 2 discussions in Q1 2026.
- XPro1595 selectively neutralizes soluble TNF, targeting neuroinflammation in precision medicine approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/0001213900-25-093930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/ea0258531-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-093930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer